Press Releases

Press Releases

June 12, 2018

hATTR Compass to provide no-cost, confidential genetic testing and genetic counseling services, potentially enabling faster diagnosis CAMBRIDGE, Mass. , June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

June 5, 2018

CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A. Moscicki , M.D., to the Company’s Board of Directors. “Rich is an experienced, well-respected industry

June 1, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the

May 29, 2018

CAMBRIDGE, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that management will present a company overview at the Jefferies Global Healthcare Conference at 9:30 a.m.

May 10, 2018

Advisory Committee members vote 12-8 to support approval CAMBRIDGE, Mass. and CARLSBAD, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S.

May 3, 2018

TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDI TM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the company through key milestones in 2019 Conference Call Webcast Thursday, May 3 , 4:30 p.m.

May 2, 2018

Program currently available in the U.S. and select countries in Europe; initiating additional countries throughout 2018 CAMBRIDGE, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United

April 26, 2018

Results to be presented show significant reduction in triglyceride levels associated with reductions of pancreatitis and burden of disease in patients with FCS CAMBRIDGE, Mass. and LAS VEGAS , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.

April 26, 2018

Webcast scheduled for Thursday, May 3rd at 4:30 p.m. Eastern Time CAMBRIDGE, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m.

April 21, 2018

Two oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of life CAMBRIDGE, Mass. , April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.